Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

Filter results: >>>>
  • Page 1 of 429
  • 1 to 25 of 10710 records
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-361 Taselisib
10.0
PI3Ka, g, d
PI3K/mTOR
-0.9902 0.90326
MDA-MB-361 Ceritinib
10.0
ALK
RTK
-0.9910 0.89628
T47D Ceritinib
10.0
ALK
RTK
-0.8550 0.88984
SUM159PT Abemaciclib
10.0
CDK4/6
Cell cycle
-0.4677 0.88367
MDA-MB-361 Cediranib
10.0
VEGFR/cKIT
RTK
-0.9803 0.88037
Hs 578T AZD7762
10.0
CHK1/2
Cell cycle
-0.5983 0.86377
MDA-MB-361 Torin2
1.0
mTOR/ATM/ATR
PI3K/mTOR
-0.9642 0.85473
MDA-MB-361 Buparlisib
10.0
pan PI3K
PI3K/mTOR
-0.9584 0.84606
Hs 578T Abemaciclib
10.0
CDK4/6
Cell cycle
-0.5825 0.84364
BT-20 Ceritinib
10.0
ALK
RTK
-0.7365 0.84133
MDA-MB-157 Ceritinib
10.0
ALK
RTK
-0.9264 0.83901
MDA-MB-468 Ceritinib
10.0
ALK
RTK
-0.7415 0.83751
HCC1428 Ceritinib
10.0
ALK
RTK
-0.8673 0.83636
MDA-MB-157 Dinaciclib
1.0
pan CDK
Cell cycle
-0.9106 0.83515
MDA-MB-157 Dinaciclib
0.31623
pan CDK
Cell cycle
-0.9006 0.83378
SUM149PT Dinaciclib
0.1
pan CDK
Cell cycle
-0.5705 0.83197
MDA-MB-134-VI Cediranib
10.0
VEGFR/cKIT
RTK
-0.9999 0.83082
HCC1428 Doxorubicin
3.1623
Chemo
Chemotherapy
-0.7396 0.82745
MDA-MB-361 Taselisib
3.1623
PI3Ka, g, d
PI3K/mTOR
-0.9425 0.82696
SUM149PT Dinaciclib
0.31623
pan CDK
Cell cycle
-0.5676 0.82399
BT-20 Dinaciclib
1.0
pan CDK
Cell cycle
-0.6979 0.82310
MDA-MB-361 Vorinostat
10.0
HDAC
Misc
-0.9392 0.81668
SUM149PT Dinaciclib
1.0
pan CDK
Cell cycle
-0.5605 0.81650
Hs 578T Cediranib
10.0
VEGFR/cKIT
RTK
-0.5723 0.81093
MDA-MB-134-VI Abemaciclib
10.0
CDK4/6
Cell cycle
-0.9986 0.81070
  • Page 1 of 429
  • 1 to 25 of 10710 records